Differences in quality of anticoagulation care delivery according to ethnoracial group in the United States: A scoping review

Sara R Vazquez; Naomi Y Yates; Craig J Beavers; Darren M Triller; Mary M McFarland

doi:10.1007/s11239-024-02991-2

Differences in quality of anticoagulation care delivery according to ethnoracial group in the United States: A scoping review

J Thromb Thrombolysis. 2024 May 11. doi: 10.1007/s11239-024-02991-2. Online ahead of print.

Authors

Sara R Vazquez¹, Naomi Y Yates², Craig J Beavers^{3

4}, Darren M Triller³, Mary M McFarland⁵

Affiliations

¹ University of Utah Health Thrombosis Service, 6056 Fashion Square Drive, Suite 1200, Murray, UT, 84107, USA. sara.vazquez@hsc.utah.edu.
² Kaiser Permanente Clinical Pharmacy Services, 200 Crescent Center Pkwy, Tucker, GA, 30084, USA.
³ Anticoagulation Forum, Inc, 17 Lincoln Street, Suite 2B, Newton, MA, 02461, USA.
⁴ University of Kentucky College of Pharmacy, 789 S Limestone, Lexington, KY, 40508, USA.
⁵ University of Utah Spencer S. Eccles Health Sciences Library, 10 N 1900 E, Salt Lake City, UT, 84112, USA.

PMID: 38733515
DOI: 10.1007/s11239-024-02991-2

Abstract

Anticoagulation therapy is standard for conditions like atrial fibrillation, venous thromboembolism, and valvular heart disease, yet it is unclear if there are ethnoracial disparities in its quality and delivery in the United States. For this scoping review, electronic databases were searched for publications between January 1, 2011 - March 30, 2022. Eligible studies included all study designs, any setting within the United States, patients prescribed anticoagulation for any indication, outcomes reported for ≥ 2 distinct ethnoracial groups. The following four research questions were explored: Do ethnoracial differences exist in 1) access to guideline-based anticoagulation therapy, 2) quality of anticoagulation therapy management, 3) clinical outcomes related to anticoagulation care, 4) humanistic/educational outcomes related to anticoagulation therapy. A total of 5374 studies were screened, 570 studies received full-text review, and 96 studies were analyzed. The largest mapped focus was patients' access to guideline-based anticoagulation therapy (88/96 articles, 91.7%). Seventy-eight articles made statistical outcomes comparisons among ethnoracial groups. Across all four research questions, 79 articles demonstrated favorable outcomes for White patients compared to non-White patients, 38 articles showed no difference between White and non-White groups, and 8 favored non-White groups (the total exceeds the 78 articles with statistical outcomes as many articles reported multiple outcomes). Disparities disadvantaging non-White patients were most pronounced in access to guideline-based anticoagulation therapy (43/66 articles analyzed) and quality of anticoagulation management (19/21 articles analyzed). Although treatment guidelines do not differentiate anticoagulant therapy by ethnoracial group, this scoping review found consistently favorable outcomes for White patients over non-White patients in the domains of access to anticoagulation therapy for guideline-based indications and quality of anticoagulation therapy management. No differences among groups were noted in clinical outcomes, and very few studies assessed humanistic or educational outcomes.

Keywords: Anticoagulation; Disparities; Ethnoracial; Quality; Racial.